profit from every ₹100 of sales.
₹0₹100
FDC
₹372.10-4.69% today
-11.6% in 1 year
1-year low ₹321.101-year high ₹434.25
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹21.53 for every ₹1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What FDC sold, what it kept, and what it did with the cash.
Sales went from ₹17.8 billion in 2023 to ₹21.7 billion in 2026, with ₹2.81 billion of profit last year.
SalesProfit
FDC handed back more cash to shareholders than it generated last year.
₹810M
Free cash flow 2026₹139M
Bought back its own shares–
Paid as dividends₹810M
Cash vs. debt₹487M vs. ₹155M
FDC vs. similar companies
FDC grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| FDC | 21.5× · Fair price | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads FDC's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 17,778 | 19,429 | 21,081 | 21,709 | |
| 10,941 | 12,509 | 13,718 | 14,600 | |
| 2,123 | 2,986 | 2,711 | 2,869 | |
| 3,003 | 4,397 | 4,155 | 4,388 | |
| 1,940 | 3,052 | 2,668 | 2,814 | |
| 11.67 | 18.58 | 16.39 | 17.29 | |
| 61.5% | 64.4% | 65.1% | 67.3% | |
| 11.9% | 15.4% | 12.9% | 13.2% | |
| 10.9% | 15.7% | 12.7% | 13.0% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 23,429 | 24,681 | 27,138 | 29,190 |
| Cash | 239 | 254 | 515 | 487 |
| Total debt | 283 | 205 | 212 | 155 |
| Total liabilities | 3,615 | 3,709 | 4,327 | 4,339 |
| 19,820 | 20,972 | 22,811 | 24,851 | |
| 166 | 164 | 163 | 163 | |
| 9.8% | 14.2% | 11.8% | 11.4% | |
| 9.8% | 14.6% | 11.7% | 11.3% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 1,549 | 2,208 | 3,176 | 2,005 | |
| 1,131 | 934 | 967 | 1,866 | |
| 418 | 1,274 | 2,208 | 139 | |
| Dividends paid | 2 | 1 | 811 | 810 |
| 1,378 | 1,550 | 0 | – | |
| – | – | – | – |
Valuation
- 21.5×
- –
- 1.54
- 2.5×
- 2.8×
- 436.2×
- 13.7×
- 0.2%
- 4.6%
- 1.3%
Profitability
- 67.3%
- 13.2%
- 13.0%
- –
- 11.4%
- 11.8%
- –
- –
- –
- –
Growth
- +6.9%
- +14.0%
- –
- –
- −0.7%
Financial health
- -0.1×
- 0.01
- –
- 76.1×
- 3.11
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 24%of 946
Top 40%of 872
Top 35%of 564
Bottom 34%of 867
Bottom 42%of 986
1.3%of the share price, paid each year
On $1,000 invested$13a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
28.8% of its profit
Room to growStretchedMore than it earns: 583.4%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
59No pass
Benjamin Graham
66Pass
Philip Fisher
63Pass
Peter Lynch
55No pass
Joel Greenblatt
33No pass
Charlie Munger
53No pass
Terry Smith
39No pass
Questions about FDC
Is FDC a good stock to buy?
A solid business at a fair price. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the FDC AI analysis
What does FDC do?
FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. It is in Drug Manufacturers - Specialty & Generic, based in Mumbai, India.
Does FDC pay a dividend?
Yes. At today's price the dividend is 1.3% a year, about 29% of its yearly profit. In 2026 it paid out ₹810 million in dividends.
Is FDC stock halal?
Yes. FDC passes our halal screen: its business is permitted and its debt is 0.2% of its market value, under the 30% limit. How we check
How has FDC stock done over the past year?
Down 11.6% over the past twelve months, to ₹372.10. It traded between ₹321.10 and ₹434.25 and is 14.3% below its high.
Who are FDC's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with FDC's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.